Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.54 |
| ▸ | NRAS | P01111 | 3/20 | 0.54 |
| ▸ | EIF2AK4 | Q9P2K8 | 7/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26359533 | 1.00 | FLT3 (0.54) | FLT3NRASEIF2AK4CYP11B1CYP11B2 | |
| SCHEMBL25990673 | 1.00 | FLT3 (0.54) | FLT3NRASEIF2AK4CYP11B1CYP11B2 | |
| SCHEMBL25989347 | 1.00 | FLT3 (0.54) | FLT3NRASEIF2AK4CYP11B1CYP11B2 | |
| SCHEMBL24231381 | 0.93 | FLT3 (0.50) | FLT3NRASEIF2AK4CYP11B1CYP11B2 | |
| SCHEMBL25991299 | 0.93 | FLT3 (0.50) | FLT3NRASEIF2AK4CYP11B1CYP11B2 | |
| SCHEMBL25988952 | 0.93 | FLT3 (0.50) | FLT3NRASEIF2AK4CYP11B1CYP11B2 | |
| SCHEMBL24231327 | 0.93 | FLT3 (0.50) | FLT3NRASEIF2AK4CYP11B1CYP11B2 | |
| SCHEMBL25988951 | 0.93 | FLT3 (0.50) | FLT3NRASEIF2AK4CYP11B1CYP11B2 | |
| SCHEMBL25991300 | 0.93 | FLT3 (0.50) | FLT3NRASEIF2AK4CYP11B1CYP11B2 | |
| SCHEMBL24231338 | 0.92 | FLT3 (0.57) | FLT3NRASEIF2AK4CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
| WO-2023150601-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK2, IRAK3 | FLT3 1/4885NRAS 259/4885EIF2AK4 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.